Filament Health Corp. (TSE:FH) has released an update.
Filament Health Corp., a natural psychedelic drug developer, reported Q4 and year-end 2023 financials and operational milestones, including the advancement of its lead drug, PEX010, for Phase 2 trials and a strategic shift away from a business combination to focus on more traditional financing. The company also achieved Health Canada approval for a Phase 2 trial of PEX010 for opioid use disorder and exported its product for clinical research in six countries. Despite operational progress, the company noted a cash position of $1.8 million and revenues of $2.1 million for the year.
For further insights into TSE:FH stock, check out TipRanks’ Stock Analysis page.
Click Here to Read the Full Original Article at TipRanks Financial Blog…
